November 10th, 2026Prizlon-Cel Nets FDA RMAT and Fast Track Designations in R/R LBCLThe anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.Read more